Skip to main content

Seasonal Allergic Conjunctivitis

4
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
KetotifenPhase 4
Alcon
AlconFORT WORTH, TX
1 program
1
KetotifenPhase 4
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionPhase 31 trial
Active Trials
NCT05591755Completed229Est. Aug 2023
Zhaoke Ophthalmology
Zhaoke OphthalmologyChina - Guangzhou
1 program
1
Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph SolnPhase 31 trial
Active Trials
NCT06212973Completed266Est. Nov 2023
Thea Pharma
Thea PharmaMA - Waltham
1 program
T1210PHASE_21 trial
Active Trials
NCT01344083CompletedEst. Feb 2012
Novartis
NovartisBASEL, Switzerland
1 program
KetotifenPHASE_41 trial
Active Trials
NCT00133627Completed229Est. Oct 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisKetotifen
Zhaoke OphthalmologyEpinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln
Bausch HealthBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Thea PharmaT1210

Clinical Trials (4)

Total enrollment: 724 patients across 4 trials

NCT00133627NovartisKetotifen

Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis

Start: Apr 2005Est. completion: Oct 2005229 patients
Phase 4Completed
NCT06212973Zhaoke OphthalmologyEpinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln

A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients

Start: Mar 2023Est. completion: Nov 2023266 patients
Phase 3Completed
NCT05591755Bausch HealthBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Start: Nov 2022Est. completion: Aug 2023229 patients
Phase 3Completed
NCT01344083Thea PharmaT1210

Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Start: Apr 2011Est. completion: Feb 2012
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.